看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Ps Multiple | 47.7x - 52.7x | 50.2x |
| Selected Fwd Ps Multiple | 71.8x - 79.4x | 75.6x |
| Fair Value | $2.90 - $3.21 | $3.05 |
| Upside | 6.6% - 17.8% | 12.2% |
| Benchmarks | Ticker | Full Ticker |
|---|---|---|
| Ovid Therapeutics Inc. | - | NasdaqGS:OVID |
| Syros Pharmaceuticals, Inc. | - | OTCPK:SYRS |
| Caribou Biosciences, Inc. | - | NasdaqGS:CRBU |
| Regen BioPharma, Inc. | - | OTCPK:RGBP |
| Vaxart, Inc. | - | NasdaqCM:VXRT |
| Relay Therapeutics, Inc. | - | NasdaqGM:RLAY |
| Select Price / LTM Sales Ratio | ||||||||
| Benchmark Companies | ||||||||
| OVID | SYRS | CRBU | RGBP | VXRT | RLAY | |||
| NasdaqGS:OVID | OTCPK:SYRS | NasdaqGS:CRBU | OTCPK:RGBP | NasdaqCM:VXRT | NasdaqGM:RLAY | |||
| Historical Sales Growth | ||||||||
| 5Y CAGR | NM- | 37.1% | 11.5% | 16.5% | 23.8% | NM- | ||
| 3Y CAGR | -86.0% | -13.0% | 1.4% | 11.4% | 218.1% | 48.9% | ||
| Latest Twelve Months | 44.4% | -95.6% | -71.0% | 0.0% | 288.9% | -60.8% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -7850.8% | -2354.4% | -668.5% | 54.2% | -12860.2% | -9090.5% | ||
| Prior Fiscal Year | -13119.4% | -636.1% | -296.1% | 432.7% | -1117.6% | -1338.7% | ||
| Latest Fiscal Year | -4589.2% | -1656.3% | -1491.9% | -366.6% | -233.3% | -3374.7% | ||
| Latest Twelve Months | -4589.2% | -25340.7% | -1491.9% | -366.6% | -233.3% | -3374.7% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | 0.2x | 0.0x | 0.9x | NA | -1.2x | 0.7x | ||
| Price / LTM Sales | 44.0x | 2.1x | 8.7x | 2.2x | 3.3x | 46.1x | ||
| LTM P/E Ratio | -1.0x | 0.0x | -0.6x | -0.6x | -1.4x | -1.4x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/S Ratio | 2.1x | 3.3x | 44.0x | |||||
| Historical LTM P/S Ratio | 39.0x | 49.3x | 1065.6x | |||||
| Selected Price / Sales Multiple | 47.7x | 50.2x | 52.7x | |||||
| (x) LTM Sales | 10 | 10 | 10 | |||||
| (=) Equity Value | 477 | 502 | 527 | |||||
| (/) Shares Outstanding | 169.5 | 169.5 | 169.5 | |||||
| Implied Value Range | 2.81 | 2.96 | 3.11 | |||||
| FX Rate: USD/USD | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 2.81 | 2.96 | 3.11 | 2.72 | ||||
| Upside / (Downside) | 3.5% | 8.9% | 14.3% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | OVID | SYRS | CRBU | RGBP | VXRT | RLAY | |
| Value of Common Equity | 25 | 1 | 87 | 1 | 96 | 461 | |
| (/) Shares Outstanding | 71.1 | 26.8 | 93.0 | 10.5 | 227.9 | 169.5 | |
| Implied Stock Price | 0.35 | 0.03 | 0.94 | 0.05 | 0.42 | 2.72 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 0.35 | 0.03 | 0.94 | 0.05 | 0.42 | 2.72 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |